Comparative Study of Helicobacter Pylori Resistance to Clarithromycin and Metronidazole and Its Association with Epidemiological Factors in A Moroccan Population.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Aug 2022
Historique:
received: 17 03 2022
entrez: 29 8 2022
pubmed: 30 8 2022
medline: 1 9 2022
Statut: epublish

Résumé

Knowledge of local antibiotic resistance is crucial to the adaption of the effective empirical first-line treatment for Helicobacter Pylori (H. pylori) infection. This study aimed to evaluate the prevalence of H. pylori resistance to clarithromycin and compare it with that of metronidazole, and highlight the impact of epidemiological factors and gastric lesions severity on H. pylori resistance. The susceptibility to clarithromycin of 96 isolates was determined by PCR-RFLP and the susceptibility to metronidazole of 185 isolates was determined by classic PCR. Our results showed that the prevalence of H. pylori resistance to clarithromycin (‎14.6%) was low compared to that recorded with metronidazole (‎62.7%). Moreover, we remarked that 7.3% of isolates were co-resistant to both antibiotics. The assessment of epidemiological factors' impact on the resistance to studied antibiotics has revealed no association. Besides, our results had demonstrated that the metronidazole and clarithromycin resistance was not related to the severity of gastric lesions. In our population, clarithromycin seems to be an effective antibiotic as long as the resistance rate of H. pylori is low. In contrast to metronidazole, it appears that this antibiotic will lose its efficacy, due to the high rate of resistance among our population. Therefore, each population must conduct their epidemiologic studies separately to survey the resistance profile of strains and choose the appropriate antibiotic, in order to avoid the failure of H. pylori eradication and the development of severe gastric diseases.

Identifiants

pubmed: 36037131
doi: 10.31557/APJCP.2022.23.8.2755
pmc: PMC9741911
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Metronidazole 140QMO216E
Amoxicillin 804826J2HU
Clarithromycin H1250JIK0A

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2755-2761

Références

Rev Inst Med Trop Sao Paulo. 2016 Dec 08;58:88
pubmed: 27982354
J Antimicrob Chemother. 2018 Feb 1;73(2):265-279
pubmed: 29077920
Folia Microbiol (Praha). 2019 Mar;64(2):143-151
pubmed: 30097895
Helicobacter. 2003 Feb;8(1):80
pubmed: 12603622
J Clin Microbiol. 1999 Mar;37(3):772-4
pubmed: 9986850
Aliment Pharmacol Ther. 2005 Jul 1;22(1):51-7
pubmed: 15963080
Braz J Microbiol. 2018 Jul - Sep;49(3):544-551
pubmed: 29452847
Microorganisms. 2022 Jan 29;10(2):
pubmed: 35208776
J Microbiol. 2006 Aug;44(4):409-16
pubmed: 16953176
Infect Dis (Lond). 2017 Sep;49(9):647-654
pubmed: 28440099
Ann Clin Microbiol Antimicrob. 2010 Aug 13;9:22
pubmed: 20707901
J Antimicrob Chemother. 2010 Feb;65(2):327-32
pubmed: 20008044
J Med Microbiol. 2012 Jan;61(Pt 1):85-93
pubmed: 21873378
Helicobacter. 2009 Jun;14(3):159-71
pubmed: 19702845
Helicobacter. 2013 Jun;18(3):206-14
pubmed: 23241101
Gut. 2013 Jan;62(1):34-42
pubmed: 22580412
Antimicrob Agents Chemother. 1999 Nov;43(11):2657-62
pubmed: 10543743
Microbes Infect. 2003 Jul;5(8):705-13
pubmed: 12814771
Am J Pathol. 2001 Feb;158(2):647-54
pubmed: 11159201
J Chemother. 2005 Jun;17(3):270-6
pubmed: 16038520
Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):397-401
pubmed: 30657582
BMC Gastroenterol. 2013 Dec 04;13:164
pubmed: 24305035
Antimicrob Agents Chemother. 2001 May;45(5):1500-4
pubmed: 11302817
Rev Prat. 2014 Feb;64(2):211-4
pubmed: 24701888
J Antimicrob Chemother. 2000 Oct;46(4):613-6
pubmed: 11020260
J Glob Antimicrob Resist. 2017 Jun;9:43-46
pubmed: 28343971
Am J Gastroenterol. 1997 Feb;92(2):248-53
pubmed: 9040200
Eur J Clin Microbiol Infect Dis. 2001 Nov;20(11):820-3
pubmed: 11783701
BMC Microbiol. 2019 Jul 4;19(1):152
pubmed: 31272365
Helicobacter. 2019 Jun;24(3):e12575
pubmed: 30873719
Helicobacter. 2015 Aug;20(4):316-20
pubmed: 25585658
Mol Microbiol. 1998 Apr;28(2):383-93
pubmed: 9622362
Microb Drug Resist. 2017 Sep;23(6):727-732
pubmed: 27996373
Gut. 2004 Sep;53(9):1374-84
pubmed: 15306603
J Pediatr Gastroenterol Nutr. 2017 Mar;64(3):e56-e60
pubmed: 27159208
Antimicrob Agents Chemother. 2009 Sep;53(9):4022-4
pubmed: 19546360
BMC Infect Dis. 2018 Apr 24;18(1):193
pubmed: 29699490
J Med Assoc Thai. 2012 Mar;95 Suppl 3:S28-35
pubmed: 22619884
World J Gastroenterol. 2005 Oct 14;11(38):6009-13
pubmed: 16273615
Gut. 2006 Dec;55(12):1711-6
pubmed: 16603633
Dig Dis Sci. 2017 May;62(5):1146-1154
pubmed: 28315035
Am J Gastroenterol. 2005 Sep;100(9):2100-15
pubmed: 16128957
J Gastroenterol Hepatol. 2004 Jun;19(6):619-25
pubmed: 15151614
J Med Microbiol. 2009 Jul;58(Pt 7):930-935
pubmed: 19502370

Auteurs

Imane Essaidi (I)

Laboratory of Helicobacter pylori and Gastric Pathologies, Institut Pasteur du Maroc, Casablanca 20360, Morocco.
Faculty of Medicine of Casablanca, IbnRochd University Hospital Center, Hassan II University, Casablanca, Morocco.

Ghizlane Bounder (G)

Laboratory of Helicobacter pylori and Gastric Pathologies, Institut Pasteur du Maroc, Casablanca 20360, Morocco.

Reda Mohamed Jouimyi (RM)

Laboratory of Helicobacter pylori and Gastric Pathologies, Institut Pasteur du Maroc, Casablanca 20360, Morocco.

Hasna Boura (H)

Laboratory of Helicobacter pylori and Gastric Pathologies, Institut Pasteur du Maroc, Casablanca 20360, Morocco.

Ilhame Elyounsi (I)

Faculty of Medicine, University of Tours, France.

Fatima-Zahra Kheir (FZ)

Laboratory of Helicobacter pylori and Gastric Pathologies, Institut Pasteur du Maroc, Casablanca 20360, Morocco.

Hakima Benomar (H)

Laboratory of Histo-Cytopathology, Pasteur Institute of Morocco, Casablanca 20360, Morocco.

Wafaa Badre (W)

Gastroenterology Department, Ibn Rochd University Hospital Center, Casablanca 20360, Morocco.

Khalid Zerouali (K)

Faculty of Medicine of Casablanca, IbnRochd University Hospital Center, Hassan II University, Casablanca, Morocco.

Fatima Maachi (F)

Laboratory of Helicobacter pylori and Gastric Pathologies, Institut Pasteur du Maroc, Casablanca 20360, Morocco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH